Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Vascular access and antithrombotic therapy in patients with acute coronary syndrome

Antithrombotic therapy plays a pivotal part in invasively managed patients with acute coronary syndrome, particularly in those who require percutaneous coronary intervention.1 In this setting, the radial artery has become the preferred vascular access site given the reduced risk of bleeding and mortality compared with femoral access.2 Although bivalirudin and unfractionated heparin with optional glycoprotein IIb/IIIa inhibitor use are both recommended for patients with acute coronary syndrome undergoing percutaneous coronary intervention, which of these is the most optimal treatment remains largely debated.